Inotiv, Inc. Expands Protein/Peptide Bioanalytical Capabilities with Acquisition of Protypia, Inc.

WEST LAFAYETTE, Ind., July 07, 2022 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV ) (the "Company", "We", "Our" or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that the Company has completed the purchase of Nashville, Tennessee based Protypia, Inc. ("Protypia"). Protypia is an emerging protein/peptide bioanalytical company offering high-quality, targeted tissue-based protein and peptide mass spectrometry. "The addition of Protypia's quantitative tissue-based large molecule bioanalytical capabilities to Inotiv's already established mass spectrometry-based bioanalytical offerings will enable clients to translate their clinical findings back into their discovery and preclinical pipelines and will be highly complementary to the GLP biomarker capabilities Inotiv is currently building at their Rockville, MD, facility," said Daniel Liebler, Protypia's Founder, President and CEO. "In addition, biopsy-based protein characterization has the potential to segment patient populations for inclusion in clinical trials studying specific mechanisms of action of novel therapeutics. Such segmentation of patients will enhance the probability of success for molecules entering late stage clinical development." John Sagartz, Inotiv's Chief Strategy Officer, added, "This highly-specialized technology and know-how significantly enhances our ability to support clients in the development of safe and effective medicines, particularly in ... Full story available on Benzinga.com